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Abstract
IL17-dependent autoimmunity to Collagen type V (Col V) has been associated with lung 
transplant obliterative bronchiolitis. Unlike the Th-1-dependent immune responses to tetanus 
toxoid (TT), the Th17 response to Col V in lung transplant patients and its Th1/17 variant 
observed in coronary artery disease patients requires IL-1β, TNFα and CD14+ cells. Given the 
involvement of the P2X7R in monocyte IL-1β responses, we investigated its role in Th17, Th1/17, 
and Th1- mediated pro-inflammatory responses. Transfer of antigen-pulsed PBMC from Col V -
reactive patients into SCID mouse footpads along with P2X7R antagonists revealed a selective 
inhibition of Col V-, but not TT -specific swelling responses. P2X7R inhibitors blocked IL-1β 
induction from monocytes, including both Col V-α1 peptide-induced (T-dependent), as well as 
native Col V induced (T-independent) responses. Significantly higher P2X7R expression was 
found on CXCR3negCCR4+/6+ CD4+ [Th17] vs. CXCR3+CCR4/6neg CD4+ [Th1] subsets in 
PBMC, suggesting that the paradigm of selective dependence on P2X7R might extend beyond Col 
V autoimmunity. Indeed, P2X7R inhibitors suppressed not only anti-Col V, but also Th1/17–
mediated allo-immunity, in a heart transplant patient without affecting anti-viral EBV responses. 
These results suggest that agents targeting the P2X7R might effectively treat Th17-related 
transplant pathologies, while maintaining Th1-immunity to infection.
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INTRODUCTION
The P2X7R has emerged as a potential site of regulation in a number of inflammatory states, 
including graft versus host disease (1), islet allograft rejection (2), chronic heart rejection 
(3), rheumatoid arthritis (4, 5) and psoriasis (6). Functioning as an ATP gated ion channel 
(7, 8), the P2X7R allows cation passage through the cell, leading to downstream activation 
of inflammasomes and production of IL-1β which is obligatory for Th17 development (9, 
10). The loss of tolerance to the minor fibrillar collagen Col V, a sequestered self antigen 
(11), was a reported common characteristic of patients listed for lung or heart 
transplantation, such as patients suffering from idiopathic pulmonary fibrosis (12), late stage 
coronary artery disease (CAD) (13, 14) and patients developing Bronchiolitis Obliterans 
Syndrome (BOS) after lung transplantation (13, 15). Investigation into the loss of tolerance 
to Col V in these patient groups has revealed that the cellular immune response to Col V is 
Th17 mediated, as it was dependent on IL-17 and CD4 T cells, but also required IL-1β, 
TNFα, and monocytes (14). Similar to the reported IL-17 mediated response to soluble 
donor antigen (allo) in kidney transplant patients (16), the IL-17 requirement was also 
associated with IL1β-dependence (14). Unlike Col V, the cellular immune response to 
Tetanus Toxoid (TT) or Epstein Barr Virus (EBV), is Th1 mediated, as it depends on IFNγ 
and not IL-17 (14, 16). Knowing that the Th17-mediated Col V response in lung transplant 
patients differs from the cellular immune response to TT in the requirements for IL1β and 
monocytes, we tested the hypothesis that P2X7R function (required for inflammasome 
activation and IL1β production in certain innate immune contexts) was required for the Th17 
cellular immune response to Col V. To test this hypothesis, we used pharmacological 
inhibitors of the P2X7R (Suramin, AZD9056 and periodate-oxidized ATP (oATP)) to 
evaluate P2X7R involvement in Col V specific cellular immune responses.
METHODS
Human Subjects
Immunologic monitoring was performed on cryo-preserved blood samples from Col V- 
reactive patients with end stage CAD (n=3), lung pathology due to primary ciliary 
dyskinesia (n=1), lung transplant (n=1) or heart transplant (n=1). Both transplant recipients 
were sampled 7–8 years post-transplantation, the lung patient at a time of normal graft 
function, the heart patient during an episode of acute rejection combined with cardiac 
allograft vasculopathy (CAV). Subject consent was obtained using human subjects 
committee-approved, written, informed consent procedures at the University of Wisconsin 
Hospital and Clinics. Blood was collected and PBMCs were processed as described 
previously (17). Where applicable, human PBMCs were incubated with CD14 (Miltenyi, 
120-001-146) or pan T-cell (Miltenyi, 120-008-788) microbeads and separated using an 
autoMACS (Miltenyi) as per the manufacturer’s protocol.
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YOPRO Uptake Assay
The YOPRO dye uptake assay and the generation of transfected HEK293 cells expressing a 
human P2X7R with normal (P2X7-wt) or loss of function (P2X7-496) activity was 
described previously (18, 19). Briefly, 5×104 transfected HEK cells were stimulated for 20 
minutes with various concentrations of AZD9056 and Suramin in the presence of 100uM 
2′-3′-O-(4-benzoylbenzoyl) adenosine 5′triphosphate (BzATP, Sigma) with 10uM YO-
PRO-1 (Invitrogen, Carlsbad, CA).
Transvivo Delayed-Type Hypersensitivity Assay
The Trans-vivo delayed type hypersensitivity (TV-DTH) assay was performed as described 
previously (14, 20). Inactivated Tetanus Toxoid was purchased from Sanofi-Aventis Pasteur. 
Human Col V was obtained from D. Brand (University of Tennessee, Memphis), and was 
prepared from placenta as described elsewhere (11). Human Col I was purchased from BD 
Pharmingen. The Col V-HLA-DR15 restricted α1 peptides, p1049 and p1439 were 
identified and synthesized as previously described (21). AZD9056 was obtained from 
Astrazeneca Pharmaceuticals (Wilmington, DE). Suramin and oATP were both purchased 
from Sigma Chemical (Saint Louis, MO). Neutralizing antibodies to IL-17 (eBioscience, 
16-7178-85), IL-1β (eBioscience, 16-7018-85) or IFNγ (eBioscience, 16-7318-85) were 
used along with normal rabbit IgG (R&D Systems, AB-105-C) where applicable.
Immunohistochemistry
Footpads from SCID mice were harvested and submitted for routine histology and 
immunohistochemical (IHC) staining as described previously (22).
Intracellular Cytokine Staining (ICCS)
ICCS experiments for IL-1β and TNFα were carried out as described previously (21). All 
samples were acquired on a FACScaliber flow cytometer and populations of IL-1β and/or 
TNFα positive cells amongst CD3−/CD14+ subsets were determined with FlowJo analysis 
software (Treestar).
P2X7R Flow Cytometry Staining
1×106 PBMCs from patients were stained for surface markers CD3 (Biolegend, 344814), 
CD14 (Biolegend, 325614), CXCR3 (BD Bioscience, 550967), CCR4 (BD Bioscience, 
561034) and CCR6 (BD Bioscience, 551773). Following surface staining, cells were fixed, 
permeabilized (Becton Dickinson, Lyse/Fix Buffer) and subsequently incubated with 1ug of 
P2X7R antibody (Aviva BioSystems, OASA05733) for 45 minutes on ice, followed by 
incubation with secondary antibody conjugated to Alexa488 (Invitrogen, A11006) for 30 
minutes. Cells were washed three times and fixed in 2%PFA. All samples were acquired on 
an LSR-II flow cytometer and frequencies of T cell or monocyte populations positive for 
P2X7R, or corrected median flouresence intensity (MFI)[MFI of sample signal – MFI of 
isotype control] of P2X7R signal were determined with FlowJo analysis software (Treestar).
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Statistical Analysis
Multiple replicates of each sample within sample groups were averaged across each assay 
and data was combined and analyzed by Mann-Whitney U and ANOVA or paired T test 
performed with Prism 5.0 (GraphPad Prism software, La Jolla, CA).
RESULTS
The cellular immune response to Col V, but not TT, in Col V reactive patients requires 
activation of the P2X7R
To examine the role of P2X7R in the cellular immune response to Col V and TT, we tested 
two pharmacological antagonists of P2X7R function, Suramin and AZD9056. We first 
found the maximum effective concentration of both P2X7R antagonists (Suramin [30uM], 
and AZD9056 [300nM]) at inhibiting P2X7R pore function (Figure 1). Next we analyzed 
TV-DTH responses to Col I, Col V and TT by PBMCs of six Col V-reactive patients in the 
presence or absence of Suramin or AZD9056 (Figure 2A). Col V elicited a significant 
increase in footpad swelling over PBS and Col I controls, consistent with previous reports 
(13, 14). Both Suramin and AZD9056 treatment of PBMCs significantly inhibited Col V 
mediated TV-DTH responses. This effect was not due to toxicity, as Suramin and AZD9056 
failed to inhibit the response to TT. Of note, similar levels of P2X7R inhibition of Col V 
responses were observed in all three groups of Col V reactive patients examined (CAD, lung 
pathology, heart transplant) (supplemental figure 1). Figure 2B illustrates the alteration in 
footpad histology of Col V versus TT stimulated PBMCs in the presence of a P2X7R 
antagonist, Suramin. H&E staining of Col V or TT stimulated, PBMC-injected, mouse 
footpads revealed a robust infiltration by mononuclear and polymorphonuclear cells 
extending into the skin and skeletal muscle. The Col V-stimulated pro-inflammatory 
response was dramatically decreased in the presence of both Suramin (Figure 2B) and 
AZD9056 (data not shown). Human cells were limited to a highly focused area in the sub-
dermal fatty tissue, with few Ly6G+ mouse neutrophils present. In contrast, the TT response 
exhibited a diffuse infiltration pattern of CD45+ hematopoietic cells, human CD68+ 
macrophages and Ly6G+ mouse neutrophils both in the presence and absence of P2X7R 
inhibitors, This histological observation was consistent with the TV-DTH response we 
observed for each sample.
HLA-DR restricted Col V peptide epitopes stimulate Col V specific cellular immunity in a 
P2X7R dependent manner
We recently identified 2 peptides, p1049 and p1439 located within the immunogenic α1(V) 
chain of the Col V molecule that bind to DR15 and induce a Th17 response in PBMCs of 
Col V-reactive DR15+ patients, and in a DR15neg recipient of a DR15+ lung transplant (21). 
We hypothesized that these short peptides, lacking α-helical structure or post-translational 
modifications of the parent molecule, will stimulate Th17 cells solely as p/MHC complexes 
on APCs while circumventing any direct activation of the monocyte. To address whether or 
not P2X7R antagonists could inhibit TV-DTH responses stimulated by Col V DR-specific 
peptides, we tested PBMCs from 3 DR15+ Col V-reactive patients. Figure 3A shows that 
TV-DTH responses to Col V peptides p1049 and p1439, recapitulated that of whole Col V. 
Like the response to Col V, both p1049 and p1439 induced swelling was significantly 
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inhibited by Suramin and AZD9056. In Figure 3B, representative H&E staining of footpads 
24 hours after injection of p1439 or p1049 stimulated PBMCs shows both Suramin and 
AZD9056 cause a dramatic decrease in the DR restricted peptide induced swelling.
T cell dependent and independent production of IL-1β and TNFα by monocytes in 
response to Col V occurs in a P2X7R sensitive manner
We have previously shown that Col V or Col V-α1 synthetic peptides can stimulate IL-1β 
production by monocytes cultured overnight in the presence of responder Th17 cells (21). 
Therefore, we examined whether P2X7R inhibition blocks the production of IL-1β or TNFα 
from monocytes in Col V and α1-peptide stimulated whole PBMCs, and as a control for 
possible T-independent effects, in cultures of isolated monocytes. Furthermore, since the 
Col V molecule, containing numerous post translational modifications (23) could potentially 
activate the T cell as well as the antigen presenting cell for Col V, the monocyte, through 
Damage Associated Molecular Patterns (DAMPs) interactions, we investigated whether Col 
V and DR-restricted peptides could stimulate monocytes directly by separating monocytes 
from PBMCs and stimulating isolated monocytes. Figure 4A shows representative flow 
plots of Col V, p1049 and p1439 stimulated PBMCs, in the presence or absence of Suramin 
or AZD9056. Overnight stimulation of PBMCs with Col V, p1049 or p1439 caused a 
significant increase in the percentage of IL-1β and TNFα from CD3−/CD14+ populations. 
Furthermore, the Col V, p1049 and p1439-stimulated production of IL-1β (Figure 4B top) 
and TNFα (Figure 4B bottom) in PBMC overnight cultures was significantly inhibited by 
P2X7R antagonism. Unlike the Col V or peptide response, LPS stimulated IL-1β and TNFα 
production was unaffected by either Suramin or AZD9056 (supplemental figure 2). To 
investigate whether Col V or DR-restricted peptides could directly stimulate isolated 
monocytes to produce IL-1β or TNFα, we performed ICCS assays on 2×105 MACS 
separated monocytes. (Figure 4C) In comparison to monocytes in whole PBMCs exposed to 
Col V (black bars), in the absence of T cells, Col V stimulated a lower but significant 
increase in IL-1β and TNFα from isolated monocytes (grey bars, left and right), a response 
that was sensitive to P2X7R antagonism (supplemental figure 3). Unlike the response of 
isolated monocytes to whole Col V, both p1049 and p1439 failed to increase IL-1β or TNFα 
production in isolated monocytes.
Inhibition of P2X7R function on both monocytes and T cells is required to block Th17 
cellular immune responses in Col V reactive patients
To examine whether P2X7R function on the monocyte or T cell defines the Col V response 
in our patient cohort, we used another P2X7R antagonist, oATP. oATP inhibits P2X7R 
function by covalently binding to the P2X7R (3, 24). This inhibitor, unlike Suramin or 
AZD9056, irreversibly inhibits P2X7R function on treated cells alleviating concerns 
regarding potential drug wash off or release. Isolated monocytes and T cells from Col V 
reactive patients were loaded with oATP. Figure 5 shows that oATP treated whole PBMCs 
exhibit a significant decrease in Col V stimulated footpad swelling, similar to that observed 
with Suramin and AZD9056. When isolated monocytes were treated with oATP and added 
to untreated autologous T cells, there was no significant decrease in the Col V response. 
Similarly, when oATP treated T cells were added to untreated autologous monocytes, there 
was no significant reduction in the Col V response. However, when both monocytes and T 
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cells were separately treated with oATP, and added together and stimulated with Col V, 
there was a significant reduction in the Col V stimulated swelling response. This result 
indicates that inhibition of P2X7R function on both T cells and monocytes is necessary for 
inhibiting the pathogenic cellular immune response in Col V-reactive patients.
Chemokine Receptor Defined T cell Subsets Express Different Levels of P2X7R
The use of chemokine receptor expression profiles has proven reliable for identifying 
subsets of IFNγ or IL-17 producing T cells (25, 26). Most notably, Th1-IFNγ producing T 
cells can be identified by CXCR3 expression (25, 27, 28), whereas IL-17 producing cells 
can be identified by the expression of CCR4 and CCR6 (29–32). With a clear effect of 
P2X7R antagonists on inhibiting cellular immunity to Col V (IL-17 dependent) but not TT 
(IFNγ dependent) we decided to investigate whether IL-17 producing T cell subsets have 
higher expression of P2X7R as opposed to their IFNγ producing counterparts. In addition, 
we also investigated monocyte expression levels of P2X7R. In figure 6A, representative 
flow plots from a Col V reactive patient show P2X7R expression is highest on monocytes 
(CD14+/CD3−), followed by CXCR3−/CCR4+/CCR6+ T cells, and finally CXCR3+/CCR4−/
CCR6− T cells, as assessed by Median Flourescence Intensity (MFI) of P2X7R staining. 
This trend of expression was relatively consistent within our patient cohort. Corrected MFI 
data for each Col V reactive patient was compiled and shows that monocytes have 
significantly higher expression of P2X7R than CXCR3+/CCR4−/CCR6− T cells and trend 
toward higher P2X7R expression than CXCR3−/CCR4+/CCR6+ T cells. Furthermore, 
CXCR3−/CCR4+/CCR6+ T cells have significantly higher expression of P2X7R than 
CXCR3+/CCR4−/CCR6− T cells (Figure 6B, top). Investigation of the frequency of P2X7R 
positive cells within monocyte or T cell subset populations illustrates that there are 
significantly higher frequencies of P2X7R positive cells in monocytes and Th17 populations 
as compared to Th1 (Figure 6B, bottom).
Differential requirement for P2X7R function in viral vs. alloimmune TV-DTH responses in 
transplant recipients
The finding of differential P2X7R expression on circulating Th1 vs Th17 cells suggested 
that we broaden the scope of our inquiry into P2X7R dependency of T cell-mediated 
immunity in transplant patients. To do this, we looked at the P2X7R requirement of TV-
DTH responses to allo-antigen and EBV viral proteins, in addition to Col V and TT in a 
heart transplant patient with mixed chronic and acute rejection, as well as in a well 
established cohort of chronic kidney rejectors. Figure 7A shows TV-DTH responses to Col 
V and allo-antigens. A biopsy taken at the time of leukapheresis revealed active acute 
rejection level 3A and CAV as indicated by luminal occlusion of arterioles (Supplemental 
Figure 4). Both Col V and allo TV-DTH responses were inhibited by Suramin and 
AZD9056. In addition, IL-17 and IL-1β neutralization dramatically inhibited TV-DTH 
responses to both Col V and the allo-indirect pathway. Of note, IFNγ neutralizing antibody 
also inhibits the cellular immune response to both Col V and the allo-indirect pathway, 
indicating that this patient exhibits a Th1/17 response in the face of Col V or allo-challenge. 
Figure 7B shows the P2X7R and cytokine dependency of both TT (open) and EBV 
(checkered). Both TT and EBV show no decrease in TV-DTH responses in the presence of 
Suramin and AZD9056. Similarly, IL-17 and IL-1β neutralization do not decrease their 
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cellular immune responses. Only neutralization of IFNγ reduced the response to TT and 
EBV. To further investigate P2X7R sensitivity of the allo-indirect response versus anti-viral 
responses to EBV, we used a group of chronic kidney rejectors in the TV-DTH assay in 
conjunction with P2X7R antagonists and antibody neutralization strategies. Figure 7C shows 
TV-DTH responses to allo (left) and EBV (right) antigens. AZD9056 and Suramin both 
significantly inhibit Allo induced swelling, while exhibiting no effect on the EBV response. 
Furthermore, the allo-indirect response in this chronic kidney rejector group was 
significantly inhibited by neutralization of IFNγ, IL-17, IL-1β and TNFα (Figure 7D).
DISCUSSION
We have previously shown that IL-1β and TNFα are required for the IL-17 mediated cellular 
immune response to Col V (13, 14). More recent reports have shown that innate derived 
signals, including IL-1β, can release IL-17 producing T cells from quiescence and into 
active IL-17 producing cells (33). While P2X7R inhibition on monocytes can be associated 
with the loss of IL-1β production (34), the effect of P2X7R inhibition on T cells is not so 
clear. What is clear from our study (Figure 6) is that both monocytes and CXCR3−/CCR4+/
CCR6+ T cells, a subset of T cells associated with IL-17 production, have higher P2X7R 
expression than the IFNγ associated T cell subset, CXCR3+/CCR4−/CCR6−. Furthermore, 
monocytes, consistent with the work of Gu et al. (35), have the highest expression of P2X7R 
amongst blood mononuclear cells. While the function of the T cell P2X7R was not directly 
investigated, there is clearly a non-redundant role for this as only when both the monocyte 
and T cell P2X7R (Figure 5) were blocked by oATP, is the cellular immune response to Col 
V lost. One way in which the function of P2X7Rs on T cells can be explained in the context 
of the Th17 mediated Col V response is through an observation made by Schenk et al (36). 
In this report, ATP signaling through T cell P2X7Rs led to sustained activation of ERK 1/2, 
causing altered phosphorylation of a family of T cell related transcription factors, the 
Nuclear Factor of Activated T cell (NFAT). In this study, inhibition of T cell P2X7Rs with 
oATP blocked ERK 1/2 activation, leading to T cell anergy (36). Interestingly, we found 
that an ERK 1/2 inhibitor (U0126) blocked the Col V-TV-DTH response to similar levels 
observed with P2X7R antagonists (supplemental Figure 5). Consistent with Th17 but not 
Th1 sensitivity to P2X7R inhibition, U0126 did not inhibit the TT response. It’s possible 
that the role of P2X7Rs on T cells involves releasing Th17 cells from the constraint of 
intrinsic regulation of TCR signaling. It has been suggested that CD161+ T cells, which 
comprise the bulk of CD4 and CD8 IL-17 producing T cells, have an intrinsic regulation of 
TCR signal upon contact with APCs (33). The P2X7R-ERK cascade may unlock the 
intrinsic regulation of the TCR signal, allowing rapid secretion of IL-17. This cascade may 
function independently of the IL-1 receptor signaling pathway through which monocyte 
derived IL-1β promotes IL-17 release (33).
It is now clear that the Col V- α1-derived 15mer peptides are sufficient to elicit a response 
in the TV-DTH assay equivalent to that of the whole protein (21). The response to peptides 
of the α1(V) chain, which represents the immunogenic portion of the Col V [α1α2] hetero-
trimer (14), was also exquisitely sensitive to P2X7R inhibition, both in vivo (Figure 3) and 
in vitro (Figure 4). Since the peptides can only induce cellular immune responses via the 
TCR interaction with pMHC-II complexes on the monocytes, this finding was consistent 
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with the critical importance of innate immune signaling for optimal TCR function in Th17 
cells.
The observation that Col V also stimulated IL-1β and TNFα in isolated monocytes in a 
P2X7R dependent manner, is consistent with the idea that Col V, a heavily post 
transcriptionally modified protein (23), can activate leukocytes directly as previously 
reported for lung epithelial cells in culture (37). How this occurs, and whether Pattern 
Recognition Receptors (PRRs) are involved is unclear. The downstream signaling from 
activated P2X7Rs can lead to inflammasome activation (38, 39). This activated complex of 
proteins is responsible for the processing of pro IL-1β/IL-18 into the mature IL-1β and IL-18 
proteins (18, 40, 41). While multiple mechanisms for the secretion of IL-1β in response to 
LPS exist (42), Col V activation of monocyte IL-1β would appear to utilize a prototypical 
P2X7R-dependent Nlrp3 inflammasome pathway, consistent with that reported by Jankovic 
et al as a potential regulator of acute graft-versus-host disease (43). In this study, the authors 
found that removal or deletion of IL-1β or Nlrp3 inflammasome components increased allo-
reactive T cells and decreased IL-17 producing T cells. Furthermore, a recent report from 
Lasiglie et al (34) underscored the importance of IL-1β/inflammasome functioning in the 
regulation of Th17 responses in patients with cryopyrin-associated periodic syndrome 
(CAPS). They reported a naturally occurring mutation in NLRP3, an important member of 
the inflammasome complex, within the CAPS patient population, caused enhanced IL-1β 
production from monocytes, and subsequent increased IL-17 serum levels and production in 
vitro (34). While this report deals with mutations in the inflammasome pathway, the 
evidence strongly supports a role for IL-1β driving Th17 effector functions, similar to what 
we observe in our Col V reactive patients.
Our data suggest that there are multiple ways that monocytes can be activated during 
immune responses to Col V, including: 1) through direct interaction with intact Col V 
protein, a component of “pro-inflammatory matrix” (44, 45), 2) as a result of TCR 
interaction with DR-bound α1(V) peptide on the monocyte APC and 3) by interaction with 
IL-17 [its receptor being abundantly expressed by monocytes (46)]. Consistent with the TV-
DTH results, we also observed that the Col V-specific peptides increased IL-1β production 
in whole PBMCs, albeit at a lower level than observed with whole Col V, and in a P2X7R 
dependent fashion. Since the peptides are only working through TCR-MHC interactions 
(Figure 4: i.e. peptides failed to activate monocytes directly), the monocyte would not 
receive the same amount of stimulation with Col V-peptides as it would with the whole Col 
V molecule. The coordinated signaling through P2X7Rs on both the monocyte and T cell 
may release Th17 effector function previously held in check.
We have previously shown that kidney graft chronic rejectors made anti donor antigen 
responses in the TV-DTH assay that were inhibited by neutralizing both IFNγ and IL-17 
(16). Herein, we report that allo-indirect responses of chronic kidney rejectors are also 
sensitive to IL-1β and TNFα neutralization as well as P2X7R inhibitors. One important 
conclusion from this study is that P2X7R inhibition in a heart transplant patient or a group 
of chronic kidney rejectors does not just selectively block the cellular immune response to 
sequestered self antigens like Col V, but also inhibits the allo-response to donor antigen, 
while not affecting the viral (EBV) or bacterial (TT) response (Figure 7). In both groups of 
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chronic rejectors, both the Col V and indirect allo-response were dependent on both IL-17 
and IFNγ, indicating a Th1/Th17 response, whereas the EBV and TT responses were purely 
IFNγ dependent. Since P2X7R inhibitors appear to selectively inhibit the self-and allo-
responses while maintaining viral and bacterial immune responses, the use of specific 
inhibitors to P2X7R may be ideal for anti-rejection drugs as viral and bacterial immunity 
would be unaffected while immune responses to allo- and self would be attenuated.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Dose Response of Suramin and AZD9056 inhibition of P2X7R function in stably 
transfected HEK293 cells
5×105 HEK cells stably transfected with either WT P2X7R (P2X7-wt) or an inactive P2X7 
receptor construct (P2X7-496) were treated with 100uM BzATP and 10uM YOPRO with or 
without Suramin (0.1–100uM) or AZD9056 (1–1000nM) for 20 min at room temperature as 
described previously (18). Fluorescent signal was determined by plate reader and quantified 
data from at least two individual experiments were performed.
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Figure 2. The cellular immune response to Col V, but not TT, in Col V reactive patients requires 
activation of the P2X7R
(A) The Col V reactive group is comprised of 3 CAD patients, 2 lung pathology patients, 
and 1 heart transplant patient. Responses to Col V (5ug), and the recall antigen TT (25ug) 
are shown with and without treatment of the P2X7R antagonists, Suramin (30uM) and 
AZD9056 (300nM) in PBMCs from all Col V reactive patients. PBMCs treated with Col I 
(5ug) were also used as a negative control. All treatment values represent the observed TV-
DTH response for the respective group minus the PBS control. Data are from 6 individual 
patients, repeated 2–5 times each. * denotes a statistically significant inhibition of the Col V 
response (Suramin, p<.008; AZD9056, p<.005). (B) Representative H&E (x20), human 
CD45 haemotopoetic cell (x20), human CD68 phagocytic vesicle containing cells (x20) and 
mouse neutrophil Ly6G (x20) stained footpads following Col V, TT and or P2X7R 
antagonist treatment. Inset numbers represent the TV-DTH response observed from each 
respective footpad.
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Figure 3. Col V DR specific peptides increase Col V specific cellular immunity in a P2X7R 
dependent manner
(A) TV-DTH responses from intact Col V (5ug), or α1(V) peptides p1049 (5ug) and p1439 
(5ug) were used to stimulate TV-DTH responses by PBMC from 3 DR15+ Col V-reactive 
patients. Both p1049 and p1439 stimulated a swelling that was significantly inhibited by 
both Suramin (1049 p<.02, 1439 p<.01) and AZD9056 (1049 p<.007, 1439 p<.009). Data 
are from 3 DR15+ Col V- reactive patients. Experiments were repeated at least 2 times. * 
Denotes statistical significance from respective peptide stimulation. (B) Representative 
H&E staining (20X) from Col V-DR-specific peptide stimulated PBMCs with and without 
P2X7R inhibition. Inset numbers represent the TV-DTH response observed from each 
respective footpad.
Sullivan et al. Page 15
Am J Transplant. Author manuscript; available in PMC 2015 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4. T-Dependent and T-Independent Col V and peptide stimulated production of IL-1β 
and TNFα in Col V reactive patients requires P2X7R activity
1×106 PBMCs from Col V reactive patients were stimulated overnight with Col V (5ug), 
p1049 (5ug) or p1439 (5ug) in the presence of Brefeldin A with or without Suramin (30uM) 
or AZD9056 (300nM). Representative flow plots (A) and quantified flow cytometry data (B) 
illustrate that Col V (p<.009), p1049 (p<.03) and p1439 (p<.02) stimulate IL-1β and TNFα 
[Col V (p<.007), p1049 (p<.009), p1439 (p<.009)] production in whole PBMCs from 
CD3−CD14+ populations. The production of IL-1β and TNFα elicited from Col V, p1049 
and p1439 was sensitive to P2X7R antagonists in all cases. [IL-1β: Suramin, p<.02 for all 
three agonists; AZD9056, p<.02 for all three agonists. TNFα: Suramin, p<.01 for all three 
agonists; AZD9056, p<.008 for all three agonists]. Inset numbers on flow plots represent the 
frequency of respective cytokine positive populations in that quadrant. To investigate 
whether Col V or DR-restricted peptides could directly stimulate isolated monocytes to 
produce IL-1β or TNFα, 2×105 MACS separated monocytes were stimulated with Col V 
(5ug), p1049 (5ug) or p1439 (5ug) (Figure 4C). IL-1β and TNFα production from Col V and 
peptide stimulation in whole PBMCs (black bars) and isolated monocytes (grey bars) is 
shown. Col V, but not DR-restricted Col V peptides, stimulated a significant increase in 
IL-1β (p<.04) and TNFα (p<.01) from isolated monoctytes. All Peptide data is from the 3 
DR15+ Col V- reactive patients. Experiments were repeated at least twice. *Denotes 
statistical significance from respective media control. #Denotes statistical significance from 
respective Col V or peptide stimulation.
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Figure 5. The P2X7R function on both monocytes and T cells is required for the Col V cellular 
immune response in Col V reactive patients
Whole PBMCs, MACs separated monocytes, or MACs separated T cells were treated with 
Suramin (30um), AZD9056 (300nM) or preloaded with oATP (300uM, 3 hour pretreatment) 
and subsequently stimulated with Col V (5ug). Whereas all three P2X7R antagonists 
blocked Col V responses in PBMCs or Col V reactive patients, groups of isolated monocytes 
loaded with oATP added to autologous untreated T cells, or oATP treated T cells added to 
autologous untreated monocytes, failed to inhibit Col V induced swelling. Only oATP 
treatment of both monocytes and T cells lead to significant inhibition of Col V responses. 
Data are from all 6 Col V reactive patients, repeated at least twice.
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Figure 6. Chemokine Receptor Expression Defined T cell Subsets Express Different Levels of 
P2X7R
1×106 PBMCs were stained with surface markers CD14, CD3, CD4, CXCR3, CCR4 and 
CCR6. Following surface staining, cells were lysed/fixed and subsequently stained for 
P2X7R (Aviva Biosystems). Described populations of IFNγ producing (CXCR3+/CCR4−/
CCR6−) and IL-17 producing (CXCR3−/CCR4+/CCR6+) T cell subsets, along with 
monocyte populations (CD3−/CD14+) were then analyzed for relative P2X7R expression. 
(A) Gating populations and relative P2X7R expression from whole PBMCs for IFNγ and 
IL-17 producing T cell subsets as well as monocytes. (B) Quantified flow cytometry staining 
of the corrected Median Flouresence Intensity (MFI of sample signal – MFI of isotype 
control) (top) and relative frequency of P2X7R expression amongst Th1, Th17 or monocyte 
populations (bottom). Data is from all 6 Col V reactive patients.
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Figure 7. Differential requirement for P2X7R function in viral vs. allo-immune TV-DTH 
responses in heart and kidney transplant patients
(A) TV-DTH responses to Col V (black) and soluble donor antigen (allo) are shown in the 
presence or absence of P2X7R antagonists, or neutralizing antibodies to IL-17, IL-1β or 
IFNγ. The TV-DTH response to self antigen (hashed bar) is also shown for comparison. (B) 
TV-DTH responses to TT or EBV in the presence of P2X7R antagonists or neutralizing 
antibodies to IL-17, IL-1β and IFNγ are illustrated. Data in A and B is from 1 heart 
transplant patient repeated at least twice. (C) TV-DTH responses in chronic kidney rejector 
patients to Allo or EBV in the presence or absence of P2X7R antagonists. Allo-responses 
were significantly inhibited by AZD9056 (p<.03) and Suramin (p<.02), while EBV 
responses showed no significant inhibition. (D) TV-DTH responses in chronic kidney 
rejector patients to Allo in the presence or absence of neutralizing antibodies (10ug) to 
IL-17, IL-1β, TNFα and IFNγ were significantly inhibited at a level of p<.02. Data in C and 
D are from 5 chronic kidney rejector patients.
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